C19orf12

Across TCGA pan-cancer cohorts, C19orf12 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated C19orf12 data layer compared with 27 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher C19orf12 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated C19orf12 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

PDAC and LSCC are the cancer types where C19orf12 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.919	0.562	<.001	21	view →
LSCC	DFS	Median	II,III,IV	1.000	0.571	.030	2	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

C19orf12–PDAC (DFS)

Open the PDAC breakdown →